

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-10: (Withdrawn)

Claim 11. (Currently Amended) A method of preventing or treating a disorder characterized by amyloid deposition in a mammalian subject, comprising administering to the subject a dosage of an agent effective to produce an immune response comprising antibodies against an amyloid component characteristic of said disorder and an adjuvant that augments the immune response to the amyloid component, and thereby preventing or treating the disorder.

Claim 12. (Currently Amended) The method of claim 11, wherein said amyloid component is a fibril protein or fibril peptide.

Claim 13. (Currently Amended) The method of claim 11+2, wherein the amyloid component is said immune response is directed to fibril component derived from a precursor protein selected from the group consisting of Serum Amyloid A protein (ApoSSA), immunoglobulin light chain, immunoglobulin heavy chain, ApoAI, transthyretin, lysozyme, fibrogen  $\alpha$  chain, gelsolin, cystatin C, Amyloid  $\beta$  protein precursor ( $\beta$ -APP), Beta<sub>2</sub> microglobulin, prion precursor protein (PrP), atrial natriuretic factor, keratin, islet amyloid polypeptide, a peptide hormone, and synuclein; including mutant variant proteins associated with hereditary amyloidosis; protein fragments or peptides thereof.

Claim 14. (Original) The method of claim 13, wherein said agent induces an immune response directed against a neoepitope formed by said amyloid component with respect to said precursor protein.

Claim 15. (Original) The method of claim 13, wherein said amyloid component is selected from the group consisting of AA, AL, ATTR, AapoA1, Alys, Agel, Acys, A $\beta$ , AB<sub>2</sub>M, AScr, Acal, AIAPP and synuclein-NAC fragment.

Claim 16. (Original) The method of claim 15, wherein said agent is selected from the group consisting of AA, AL, ATTR, AapoA1, Agel, Acys, A $\beta$ , AB<sub>2</sub>M, AScr, Acal, AIAPP and synuclein-NAC fragment.

Claim 17. (Original) The method of claim 11, wherein said agent is effective to induce an immunogenic response against at least two different amyloid components.

Claim 18. (Original) The method of claim 17, wherein said administering includes administering at least two amyloid fibril components.

Claim 19. (Original) The method of claim 11, wherein said agent is a peptide linked to a carrier protein.

Claim 20. (Canceled)

Claim 21. (Currently Amended) The method of claim ~~20~~11, wherein said adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, and alum and Freund's adjuvant.

Claim 22. (Currently Amended) The method of claim 11, wherein said ~~immunological~~ immune response is characterized by a serum titer of the antibodies of at least 1:1000 with respect to said amyloid component.

Claim 23. (Currently Amended) The method of claim 22, wherein said serum titer of the antibodies is at least 1:5000 with respect to said fibril component.

Claim 24. (Currently Amended) The method of claim 11, wherein said ~~immunological~~ immune response is characterized by a serum ~~amount~~ titer of the antibodies to the

PATENT

Appl. No. 09/724,575  
Amdt. dated May 21, 2003  
Reply to Office Action of November 21, 2002

amyloid component corresponding to greater than about four times higher than a serum-level titer of ~~immunoreactivity~~ antibodies measured in a pre-treatment control serum sample.

310  
Claim 25. (Currently Amended) The method of claim 24, wherein said serum amount titer of ~~immunoreactivity~~ the antibodies is measured at a serum dilution of about 1:100.

Claims 26-57: (Canceled)

---

**Amendments to the Drawings:**

The first attached replacement drawing sheet includes changes to Fig. 11. This sheet, which includes Fig. 11 and Fig. 12, replaces the original drawing sheet which includes Fig. 11 and Fig. 12.

The second attached replacement drawing sheet includes changes to Fig. 15A. This sheet replaces the original drawing sheet which includes Fig. 15A.

The third attached replacement drawing sheet includes changes to Fig. 15B. This sheet replaces the original drawing sheet which includes Fig. 15B.

The fourth attached replacement drawing sheet includes changes to Fig. 15C. This sheet replaces the original drawing sheet which includes Fig. 15C.

The fifth attached replacement drawing sheet includes changes to Fig. 15D. This sheet replaces the original drawing sheet which includes Fig. 15D.

The sixth attached replacement drawing sheet includes changes to Fig. 15E. This sheet replaces the original drawing sheet which includes Fig. 15E.

The seventh attached replacement drawing sheet includes changes to Fig. 16. This sheet replaces the original drawing sheet which includes Fig. 16.

Attachments: Seven Replacement Drawing Sheets